Sign inJoin waitlistJoin the waitlist

AS

Alison Schram

Associate Attending Physician · New York Presbyterian Hospital

Credentials: · · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2015–2017
Internal Medicine
Brigham and Women's Hospital
2012–2015
Perelman School of Medicine at the University of Pennsylvania
2008–2012

Research

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Nature · 2018 · 645 citations
Genome doubling shapes the evolution and prognosis of advanced cancers
Nature Genetics · 2018 · 515 citations

DH
David Hyman
32 papers
AD
Alexander Drilon
27 papers
David Solit
11 papers
JH
Jaclyn Hechtman
10 papers
JH
James Harding
10 papers
ML
Marc Ladanyi
10 papers
BL
Bob Li
7 papers
JB
José Baselga
7 papers
KJ
Komal Jhaveri
7 papers
ER
Ezra Rosen
6 papers
GI
Gopa Iyer
6 papers
LS
Lillian Smyth
6 papers

Clinical trials

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2018–2025
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2017–2023
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Principal investigator · Active not recruiting · Phase 2
Partner Therapeutics, Inc.
2015–2026
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Site PI · Recruiting · Phase 2
Elevar Therapeutics
2026–2028